Pharmacokinetics, biodistribution and targeting of 111 in- labeled humanized PAM4IgG [monoclonal antibody PAM4] in pre-surgical pancreatic cancer patients.An examination of protein dose
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs Monoclonal antibody PAM4 (Primary)
- Indications Pancreatic cancer
- Focus Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 16 Dec 2008 Status changed from recruiting to discontinued.
- 09 Oct 2007 The expected completion date for this trial is now 1 Jun 2008.